5-(N,N-Hexamethylene)amiloride

From WikiMD's WELLNESSPEDIA


5-(N,N-Hexamethylene)amiloride is a derivative of the diuretic drug amiloride, which is primarily known for its role as a potassium-sparing diuretic. This compound is of interest in the field of pharmacology due to its ability to inhibit certain ion channels and transporters, particularly the sodium-hydrogen exchanger (NHE).

Chemical Structure and Properties[edit]

5-(N,N-Hexamethylene)amiloride is a modified version of amiloride, where the pyrazine ring is substituted with a hexamethylene group. This modification alters its pharmacokinetic and pharmacodynamic properties, potentially enhancing its specificity and potency against certain targets.

Molecular Formula[edit]

The molecular formula of 5-(N,N-Hexamethylene)amiloride is C12H18N4O.

Molecular Weight[edit]

The molecular weight of this compound is approximately 234.3 g/mol.

Mechanism of Action[edit]

5-(N,N-Hexamethylene)amiloride functions primarily as an inhibitor of the sodium-hydrogen exchanger (NHE), a membrane protein that plays a critical role in regulating intracellular pH and cell volume. By inhibiting NHE, this compound can affect various physiological processes, including cell proliferation, migration, and apoptosis.

Pharmacological Effects[edit]

The pharmacological effects of 5-(N,N-Hexamethylene)amiloride are largely attributed to its ability to modulate ion transport across cell membranes. This can lead to changes in cellular homeostasis and has potential therapeutic implications in conditions such as hypertension, heart failure, and certain types of cancer.

Research and Clinical Applications[edit]

Research into 5-(N,N-Hexamethylene)amiloride has focused on its potential use in treating diseases characterized by dysregulated ion transport. Studies have explored its effects in models of cardiovascular disease, cancer, and other conditions where NHE activity is implicated.

Safety and Toxicity[edit]

As with any pharmacological agent, the safety and toxicity profile of 5-(N,N-Hexamethylene)amiloride must be thoroughly evaluated. Preclinical studies are necessary to assess its potential side effects and therapeutic window.

Also see[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=5-(N,N-Hexamethylene)amiloride&oldid=6021650"